Acorda Therapeutics
E603025
Acorda Therapeutics is a biopharmaceutical company specializing in therapies for neurological disorders, particularly multiple sclerosis and other central nervous system conditions.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Acorda Therapeutics canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6563408 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Acorda Therapeutics Context triple: [fampridine, developedBy, Acorda Therapeutics]
-
A.
Juno Therapeutics
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
B.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
C.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
D.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
E.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Acorda Therapeutics Target entity description: Acorda Therapeutics is a biopharmaceutical company specializing in therapies for neurological disorders, particularly multiple sclerosis and other central nervous system conditions.
-
A.
Juno Therapeutics
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
B.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
C.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
D.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
E.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| activeIngredient | dalfampridine NERFINISHED ⓘ |
| businessModel | research, development, and commercialization of CNS therapies ⓘ |
| collaboratesWith |
academic research institutions
ⓘ
other pharmaceutical companies ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| developedProduct |
Ampyra
NERFINISHED
ⓘ
Inbrija NERFINISHED ⓘ dalfampridine NERFINISHED ⓘ |
| develops |
therapies for central nervous system conditions
ⓘ
therapies for multiple sclerosis ⓘ |
| focusesOn |
Parkinson’s disease
ⓘ
central nervous system disorders ⓘ multiple sclerosis ⓘ neurological disorders ⓘ |
| foundedBy | Ron Cohen NERFINISHED ⓘ |
| hasFounder | Ron Cohen NERFINISHED ⓘ |
| hasHeadquartersIn | Ardsley, New York, United States NERFINISHED ⓘ |
| hasKeyPerson | Ron Cohen NERFINISHED ⓘ |
| hasKeyPersonRole | Chief Executive Officer ⓘ |
| hasLanguage | English ⓘ |
| hasTherapeuticArea |
movement disorders
ⓘ
neuroinflammation ⓘ |
| hasTickerSymbol | ACOR NERFINISHED ⓘ |
| hasWebsite | https://www.acorda.com ⓘ |
| indication |
improvement of walking in patients with multiple sclerosis
ⓘ
intermittent treatment of OFF episodes in Parkinson’s disease ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| listedOn | NASDAQ ⓘ |
| operatesIn |
North America
ⓘ
international markets ⓘ |
| productBrandNameOf | Ampyra NERFINISHED ⓘ |
| regulatoryRegion | United States Food and Drug Administration jurisdiction ⓘ |
| regulatoryStatus | FDA-approved products ⓘ |
| researchArea |
remyelination
ⓘ
spinal cord injury ⓘ stroke recovery ⓘ |
| routeOfAdministration | inhalation ⓘ |
| specializesIn |
neurodegenerative diseases
ⓘ
neurorehabilitation ⓘ |
| subjectOf |
clinical trials in Parkinson’s disease
ⓘ
clinical trials in multiple sclerosis ⓘ |
| targetPatientGroup |
patients with Parkinson’s disease
ⓘ
patients with central nervous system disorders ⓘ patients with multiple sclerosis ⓘ |
| therapyType |
CNS-targeted therapies
ⓘ
small-molecule drugs ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Acorda Therapeutics Description of subject: Acorda Therapeutics is a biopharmaceutical company specializing in therapies for neurological disorders, particularly multiple sclerosis and other central nervous system conditions.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.